Fine FY20 sales, as they dropped in line with the consensus, but Q1 FY21 should ultimately be worse than expected and Q2 should show a recovery (but still negative growth). The H1 operating profit should therefore be under pressure. Remy is attractive in the mid-term, but the lack of diversification and high valuation means that we should continue to keep away from the stock at this stage.